This is a major attempt to discredit a very reputable bio venture management team that has taken over AXDX... there is absolutely nothing to the research provided by Citron Research... they have no biotechnology expertise to draw from... the recent SEC correspondence DID NOT shine any new light on the ID/AST technology underdevelopment... there has been no "exposure of fraud"... the technology works as described... and will be a "game changing" technology that will meet vast acceptance once clinical testing is complete and FDA approval is met...
The shareholder lawsuits but the ambulance chasing law firms... is only part of the SHORT selling strategy...
Despite all of this noise... AXDX continues to get significant government grant funding from NIH... and its collaborative partners include the prestigious Washington University School of Medicine in St. Louis...
This is a development stage biotechnology firm... there are little if any revenues... it is well capitalized... and well managed... the technology continues to demonstrate significant reduction in time of identification of multi-drug resistant bacteria... the technology has just received ISA 13485:2003 certifications on its initial installation... and continued expansion of its partner utilization network is occurring at present to gather more testing feedback on the device and technologies applications...
You might very well utilize this very well coordinated SHORT SCARE to find a great entry point for a company that will see PPS between $45 to $70 by mid to late 2016... when the product (which is a razor / razor blade product model)... is fully being marketed with a potential market of every hospital and micro/molecular laboratory in North America... then Europe... then Asia... then everywhere else...
GO AXDX!!!
Recent AXDX News
- Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. • PR Newswire (US) • 05/02/2024 01:30:00 PM
- Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. • PR Newswire (US) • 03/07/2024 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:32:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:31:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:45:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/05/2024 08:59:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:59:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:48:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:12:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 02:20:45 AM
- Form 424B1 - Prospectus [Rule 424(b)(1)] • Edgar (US Regulatory) • 01/23/2024 02:59:53 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:17 AM
- Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement • PR Newswire (US) • 01/19/2024 02:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 12:19:47 PM
- Accelerate Diagnostics Announces Launch of Proposed Public Offering • PR Newswire (US) • 01/16/2024 12:45:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/16/2024 12:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:03:07 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM